Introduction {#s1}
============

Flavonoids are polyphenolic compounds that are abundant in fruits and vegetables. High intake of fruits and vegetables is associated with beneficial health effects, and these effects have been attributed in part to their high content of flavonoids. The World Cancer Research Fund (WCRF) and the American Institute of Cancer Research (AICR) reported summary estimates of the effects of fruit and vegetable consumption on cancer risk \[[@B1]\]. The consumption of fruits and vegetables most likely protects against cancers of the mouth, pharynx, larynx, esophagus, and stomach; the risk of lung cancer was only associated with fruit consumption. These cancers are smoking-related cancers according to the International Agency for Research on Cancer (IARC) Monograph on tobacco smoking. Smoking is classified as the cause of cancers of the lung, oral cavity, nasal and paranasal sinuses, pharynx, larynx, esophagus, kidney, liver, uterine cervix, stomach, bladder, pancreas, as well as myeloid leukemia \[[@B2]\]. Adverse effects of flavonoids in human health are rare, but the potential for detrimental health effects is based on in vitro studies in which pro-oxidant activities have been observed \[[@B3],[@B4]\]. However, flavonoids are known to have powerful antioxidant, anti-inflammatory, and anti-tumor activities against carcinogens \[[@B5],[@B6],[@B7]\]. Tobacco contains various carcinogens that can induce free radicals and cause gene mutations and the formation of DNA \[[@B8]\]. Thus, dietary flavonoids may play a role in protecting against smoking-related cancers.

The effects of dietary flavonoids on stomach and colorectal cancer were investigated using published studies \[[@B9]\] because flavonoids have been consistently found to be inversely associated with stomach and colorectal cancers in in-vitro studies \[[@B10],[@B11],[@B12]\]. However, based on a previous meta-analysis, no clear evidence supports that dietary flavonoids are associated with a reduced risk of stomach and colorectal cancers. The health effects of flavonoids and their subclasses might differ by cancer site. The cancer site that is affected by carcinogens such as tobacco smoking might be closely related to intakes of dietary flavonoids. Thus, a meta-analysis of published case-control and cohort studies was performed to calculate summary estimates of the effects of dietary flavonoid and their subclasses on smoking-related cancer risk.

Methods {#s2}
=======

Study selection {#s2.1}
---------------

A systematic search for relevant studies published through October 31, 2012 was conducted with PubMed using the terms (cancer risk) and (flavonoid or flavonol or quercetin or kaempferol or myricetin or isorhamnetin or flavone or luteolin or apigenin or flavanone or eriodictyol or hesperetin or naringenin or flavan-3-ol or catechin or epicatechin or theaflavin or anthocyanidin or cyanidin or delphinidin or malvidin or pelargonidin or peonidin or petunidin or isoflavones). The inclusion criteria were as follows: (1) the original article described a case-control or cohort design; (2) the article reported the intake of either dietary flavonoids or subclasses of flavonoids; (3) the article reported the risk of smoking-related cancers that were defined according to the IARC monograph (cancers included those of the oral cavity, paranasal sinuses, nasal cavity, larynx, pharynx, lung, esophagus, stomach, liver, pancreas, kidney, bladder, and uterine cervix, as well as myeloid leukemia); and (4) the article reported 95% confidence intervals (CI) with adjusted odds ratios (OR) or relative risks (RR) for smoking-related cancer risk in subjects with the highest dietary flavonoid intake compared with those with the lowest dietary flavonoid intake.

Data collection {#s2.2}
---------------

Data on the authors, publication year, cancer site, country in which the study was performed, study design, study period, dietary assessment method, reported flavonoid types, included subclasses for calculation of total flavonoid intake, controlled confounders, and multivariate-adjusted OR/RR and 95% CI were collected for the meta-analysis. If the study reported only the subgroup analyses by sex, viral infection status, or ethnicity, then the summary estimate of the subgroup was used for the meta-analysis to include an example from each article. However, the articles that reported individual risk estimates by cancer sites but not an all-cancer risk were used only in the subgroup meta-analysis that was conducted by cancer site. If multiple articles reported the risk of the same cancer site from the same cohort data, then the most recently published data were selected.

Statistical analysis {#s2.3}
--------------------

All statistical analyses were performed using the Stata software package (version 10, College Station, TX). Summary estimates and the corresponding standard errors were calculated using the multivariate-adjusted OR/RR and 95% CI of selected studies and weighted by the inverse variance. The heterogeneity was tested using the I^2^ test and Q-test based on the χ^2^ statistic, considering significant statistical heterogeneity as p \< 0.1. Subgroup analyses were conducted by study design, sex, and smoking status. Publication bias was examined using Begg's tests. A subgroup analysis by smoking status was performed when the studies reported the risk in both smokers and non-smokers because the effect of smoking on cancer risk can vary by cancer site. Sensitivity analyses were performed to test the robustness of the results of the combined effects. Based on the heterogeneity of the included studies, fixed or random effects models were selected to calculate the pooled effect measures.

Results {#s3}
=======

A total of 1401 studies were examined, and the 174 studies that remained after excluding articles based on the titles and abstracts were further reviewed; 139 studies were excluded for the following reasons: 106 studies included a cancer type that was not smoking-related; 20 studies were not relevant for dietary flavonoid intake or any of the flavonoid subclasses; 6 studies were review articles; 4 studies did not report the cancer risk according to categories of flavonoid intake; 2 studies were updated with more recent studies from the same cohort; and 2 studies were not related to cancer risk ([Figure 1](#pone-0075604-g001){ref-type="fig"}). Finally, 19 case-control studies \[[@B13],[@B14],[@B15],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B24],[@B25],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31]\] and 15 cohort studies \[[@B32],[@B33],[@B34],[@B35],[@B36],[@B37],[@B38],[@B39],[@B40],[@B41],[@B42],[@B43],[@B44],[@B45],[@B46]\] were selected for the meta-analysis ([Tables 1](#pone-0075604-t001){ref-type="table"}, [2](#pone-0075604-t002){ref-type="table"}). Begg's tests for publication bias showed non-significant results.

![Flow diagram of study selection.](pone.0075604.g001){#pone-0075604-g001}

10.1371/journal.pone.0075604.t001

###### Case-control studies on dietary flavonoids and risk of smoking related cancer.

  First author \[Ref no.\] Year   Cancer site                     Country       Study period   Case N / Control N      Dietary assessment method   Reported flavonoids        Included subclasses for total flavonoids   Intake comparison, High vs. low (mg/d)                                                                                                                                                                                   Controlled confounders
  ------------------------------- ------------------------------- ------------- -------------- ----------------------- --------------------------- -------------------------- ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Garcia-Closas \[13\] 1998       Lung                            Spain         1989-1992      103/206                 Diet history                Q, K, L                                                               Median, Q: 6.58 vs. 2.5, K: 1.24 vs. 0.34, L: 0.02 vs. 0.00                                                                                                                                                              Age, area of residence, and hospital and adjusted for smoking status (never-smokers, former smokers, current smokers), total pack-years smoked, vitamin E and vitamin C intake, total carotenoid intake (a-carotene, P-carotene, lutein, and lycopene), and intake of myricetin and other specific flavonoids as indicated.
  Garcia \[14\] 1999              Bladder                         Spain         1983--1986     495/1112                Diet history                Q, K, M, L                                                            Q4 vs. Q1, Mean (SD), Case: Q: 4.8 (3.2), K: 0.97 (1.15), M: 0.23 (0.35), L: 0.39 (1.34) Control: Q: 4.8 (3.3), K: 1.03 (1.18), M: 0.21 (0.34), L: 0.38 (1.29)                                                           Matched by gender, age, area of residence, and hospital. Adjusted for smoking status (never-smokers, former smokers, current smokers), total pack-years smoked, occupational exposure (no/yes), total energy intake (by residual method), vitamin E intake, saturated fatty acid intake, and intake of other specific carotenoids or other specific flavonoids.
  Garcia-Closas \[15\] 1999       Gastric                         Spain         1987-1989      354/354                 Diet history                Q, K, M                                                               Q4 vs. Q1, Mean (SD), Case: Q: 7.1 (6.5), K: 1.2 (1.9), M: 0.65 (1.17), Control: Q: 8.6 (9.0), K: 1.4 (2.0), M: 0.70 (1.42)                                                                                              Total energy intake, intake of nitrites, nitrosamines, vitamin C, total carotenoids (α-carotene, β-carotene, lutein, and lycopene) and other specific favonoids (quercetin, kaempferol, myricetin, and luteolin).
  Stefani \[16\] 1999             Lung                            Uruguay       1993-1997      541/540                 FFQ                         T, Q, K                    F1, F2                                     Q4 vs. Q1 Case: Mean (SD) Q: 5.2(5.3), K 2.1 (3.9) Control: Q: 6.8 (7.3), K 3.2 (5.6)                                                                                                                                    Age, residence, urban/rural status, education, family history of a lung cancer in 1st-degree relative, BMI, smoking (pack-yr), and total energy and total fat intake
  Marchand \[17\] 2000            Lung                            US (Hawaii)   1992-1997      582/582                 FFQ                         T, Q, K, M, H, N           Q, K, M, H, N                              Q4 vs. Q1 (T3 vs. T1 for N)                                                                                                                                                                                              Matched by age, sex, and ethnicity. Adjusted for smoking status, duration, (duration)^2^, number of cigarettes smoked per day, and b-carotene and saturated fat intakes
  Lagiou \[18\] 2004              Lung                            Greece        1987-1989      154/145                 FFQ                         F1, F3, F4                                                            F1: per 5.0, F3: per 37.0, F4: per 5.7                                                                                                                                                                                   Age, total energy intake, smoking status (ever vs. never smokers), and pack-years (among smokers), fruit and vegetable consumption.
  Lagiou \[19\] 2004              Stomach                         Greece        1981-1984      110/100                 FFQ                         F1, F2, F3, F4, An, I                                                 F1: per 10.0, F2: per 0.3, F3: per 19.8, F4: per 135.1, An: per 40.4, I: per 2.0.                                                                                                                                        Age, gender, total energy intake, place of birth, BMI, height, years of education, smoking habits and duration of smoking, alcohol consumption, and fruit and vegetable consumption.
  Schabath \[20\] 2005            Lung                            US            1995-2003      1674/1735               FFQ                         I                                                                     ≥0.997 vs. ≤0.307                                                                                                                                                                                                        Age, sex, ethnicity, smoking status, cigarettes smoked per day, years of smoking, education, income, BMI, and total energy, where appropriate
  Bosetti \[21\] 2007             Renal                           Italy         1992-2004      767/1534                FFQ                         T, F1, F2, F3, An, I       F1, F2, F3, F4, An, I                      T: \>180.9 vs. ≤80.6, F1: \>29.9 vs. ≤13.3, F2: \>0.6 vs. ≤0.3, F3: \>57.8 vs. ≤9.6, F4: \>90.6 vs. ≤21.3, An: \>32.4 vs. ≤5.5, I: \>32.6 vs. ≤14.8                                                                      Matched by age, sex, and study center. Adjusted for period of interview, education, tobacco smoking, alcohol drinking, BMI, occupational physical activity, family history of kidney cancer, and total energy intake
  Garavello \[22\] 2007           Laryngeal                       Italy         1992 - 2000    460/1088                FFQ                         T, F1, F2, F3, F4, An, I   F1, F2, F3, F4, An, I                      T: \>221.8 vs. ≤95.5, F1: \>33.7 vs. ≤16.8, F2: \>0.7 vs. ≤0.3, F3: \>49.2 vs. ≤7.7, F4: \>110.4 vs. ≤31.2, An: \>41.1 vs. ≤8.6, I: \>32.6 vs. ≤14.7                                                                     Matched by age, sex, year of interview and area of residence. Adjusted for study centre, education, alcohol consumption, tobacco smoking, BMI, occupational physical activity and non-alcohol energy intake
  Rossi \[23\] 2007               Esophageal                      Italy         1992 - 1997    304/743                 FFQ                         T, F1, F2, F3, F4, An      F1, F2, F3, F4, An                         T: \>217.4 vs. ≤96.5, F1: \>31.9 vs. ≤15.9, F2: \>0.7 vs. ≤0.3, F3: \>58.8 vs. ≤6.4, F4: \>109.1 vs. ≤32.6, An: \>41.2 vs. ≤8.1                                                                                          Matched by age, sex, year of interview and area of residence. Adjusted for study centre, education, alcohol consumption, tobacco smoking, BMI and energy intake
  Rossi \[24\] 2007               Oral cavity and pharyngeal      Italy         1992 - 2005    805/2081                FFQ                         T, F1, F2, F3, F4, An, I   F1, F2, F3, F4, An, I                      T: \>204.0 vs. ≤83.5, F1: \>29.9 vs. ≤13.9, F2: \>0.67 vs. ≤0.3, F3: \>67.0 vs. ≤10.2, F4: \>99.6 vs. ≤23.3, An: \>33.2 vs. ≤5.3, I: \>32.5 vs. ≤14.7, (Sex and smoking status: per 1SD increment)                       Matched by age, sex, and study center. Adjusted for tobacco smoking, alcohol drinking, education, BMI, and non--alcohol energy intake
  Cui\[25\] 2008                  Lung                            US            1999-2004      558/837                 FFQ                         T, Q, K, M, H, N2, C, E    F1, F2, F3, F4, An                         T: ≥90 vs. \<30, Q: ≥7.5 vs. \<2.5, K: ≥1.5 vs. \<0.5, M: ≥0.6 vs. \<0.2, H: ≥30 vs. \<10, N2: ≥15 vs. \<5, C: ≥3 vs. \<1, E: ≥9 vs. \<3                                                                                 Matched by age, sex. Adjusted for race-ethnicity, years of schooling, smoking status, pack-years of tobacco smoking, and daily energy intake.
  Lagiou \[26\] 2008              Liver                           Greece        1995-1998      339/360                 FFQ                         T, F1, F2, F3, F4, An, I   F1, F2, F3, F4, An, I                      T: \>358.1 vs. ≤145.8, F1: \>37.3 vs. ≤21.6, F2: \>1.16 vs. ≤0.25, F3: \>120.6 vs. ≤57.0, F4: \>66.3 vs. ≤25.3, An: \>152.7 vs. ≤10.2, I: \>0.32 vs. ≤0.03                                                               Age, sex, education, tobacco smoking, and total energy intake
  Bobe \[27\] 2009                Esophageal                      US            1986-1989      161/678                 FFQ                         T, F1, F2, F3, F4, An, I   F1, F2, F3, F4, An, I                      (mg/1000kcal) T: \>107 vs. \<43, F1: \>15.9 vs. \<6.89, F2: \>4.41 vs. \<2.08, F3: \>26.2 vs. \<9.30, F4: \>60.6 vs. \<10.3, An: \>4.73 vs. \<1.45, I: \>0.019 vs. \<0.005                                               Smoking duration and intensity, geographical area, age, BMI, hot tea consumption, hard liquor consumption, beer consumption, moonshine consumption (for black men), red wine consumption, white wine consumption (except for ESCC in white men), caloric intake, education (for black men) and income
  Rossi \[28\] 2010               Stomach                         Italy         1997-2007      230/547                 FFQ                         F1, F2, F3, F4, An, I                                                 F1: \>32.3 vs. \<13.2, F2: \>0.7 vs. \<0.3, F3: \>56.8 vs. \<12.9, F4: \>79.2 vs. \<21.6, An: \>21.5 vs. \<6.2, I: \>34.3 vs. \<15.0, P: \>373.0 vs. \<339.6.                                                            Age, sex, education, year of interview, BMI, tobacco smoking, and total energy intake.
  Ekstrom \[29\] 2011             Stomach (cardia & non cardia)   Sweden        1989-1995      C81, Non420/1116        FFQ                         Q                                                                     \>11.89 vs. \<3.88.                                                                                                                                                                                                      Age, sex, socioeconomic status, number of siblings, BMI, smoking and energy and salt intake.
  Christensen \[30\] 2012         Lung                            Canada        1996-1997      f 399/ 574, m 662/851   FFQ                         T, F1, F2, F3, F4, An      F1, F2, F3, F4, An                         F1: f \<7.6 vs. ≥16.6, m: \<11.7 vs. ≥24.3, F2: f \<0.6 vs. ≥1.4, m \<0.7 vs. ≥2.1, F3: f \<18.7 vs. ≥50.3, m: \<20.8 vs. ≥64.6, F4: f \<8.7 vs. ≥249.1, m \<12.6 vs. ≥271.0, An: f \<8.0 vs. ≥15.4, m \<6.6 vs. ≥23.1   Age, sex, number of school years, mean census tract family income, ethnic group, respondent status, comprehensive smoking indicator, occupational exposure to carcinogens, BMI, number of alcoholic drinks/day and total energy intake
  Rossi \[31\] 2012               Pancreas                        Italy         1991-2008      326/652                 FFQ                         F1, F2, F3, F4, An                                                    F1: \>31.1 vs. ≤13.9, F2: \>0.7 vs. ≤0.3, F3: \>61.0 vs. ≤9.6, F4: \>97.9 vs. ≤23.8, An: \>31.1 vs. ≤4.5                                                                                                                 Matched by age, sex, and center of study. Adjusted for year of interview, education, history of diabetes, tobacco smoking, alcohol drinking and non-alcohol energy intake

T: total flavonoid intake, Q: quercetin, K: kaempferol, M: myricetin, L: luteolin, H: hesperetin, N: naringenin, C: catechin, E: epicatechin, F1: flavonols, F2: flavones, F3: flavanones, F4: flavan-3-ols, An: anthocyanidins, I: isoflavones, P: proanthocyanidins, Q4: highest quartile, T3: highest tertile

10.1371/journal.pone.0075604.t002

###### Cohort studies on dietary flavonoids and risk of smoking related cancer.

  First author \[Ref no.\] year   Cancer site                                        Country             Follow-up (y)   Case (n)                   Dietary assessment method   Reported flavonoids                  Included subclasses for total flavonoids   Intake comparison, High vs. low (mg/d)                                                                                                                                                                                             Controlled confounders
  ------------------------------- -------------------------------------------------- ------------------- --------------- -------------------------- --------------------------- ------------------------------------ ------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Arts\[32\] 2001                 Lung                                               Mixed               \<10            42                         Diet history                F4                                                                              123.7 vs.25.2 (mean)                                                                                                                                                                                                               Age, physical activity, total energy intake, alcohol intake, smoking status, pack-years of smoking, BMI, coffee, fiber, vitamin C, vitamin E, β-carotene
  Hirvonen \[33\] 2001            Stomach, Urothelial^a^                             Finland             6.1 (median)    S 111/U 156                Diet history                T                                    F1, F2                                     16.3 vs. 4.2 (median)                                                                                                                                                                                                              Age and supplementation group.
  Arts \[34\] 2002                Pancreas, Lung, Kidney and renal pelvis, Bladder   US                  \<13            P 130/L 549/K 114/ B 103   FFQ                         F4                                                                              75.1 vs. 3.6 (mean)                                                                                                                                                                                                                Age, total energy intake, BMI, waist-to-hip ratio, physical activity, pack-years of smoking, smoking status, number of years since quit smoking, alcohol intake, and total fruit and vegetable consumption
  Knekt \[35\] 2002               Stomach, Lung, Urinary organs                      Finland             \<30            S 74/ L 169/ U 81          Diet history                T, Q, K, M, H, N                     F1, F2, F3                                 T: f \>39.5 vs. 8.5, m 26.9 vs. 4.3, Q: f \>4.7 vs. \<1.8, m 3.9 vs. \< 1.5, K: f \>0.9 vs. \<0.2, m 0.8 vs. 0.1, M: f \>0.2 vs. \<0.03, m 0.11 vs. 0.06, H: f \>26.8 vs. \<3.2, m 15.4 vs. 0, N: f \>7.7 vs. \<0.9, m 4.7 vs. 0   Age, sex, geographic area, occupation, smoking, and BMI.
  Wright \[36\] 2004              Lung                                               Finland             11.3 (median)   1787                       FFQ                         T                                    F1, F4                                     Q4 vs. Q1 (IQR: 12.76)                                                                                                                                                                                                             Energy intake, age, number of cigarettes smoked per day, number of years of smoking, intervention assignment, BMI, and educational level.
  Nothlings \[37\] 2007           Pancreas                                           US (multi-ethnic)                   529                        FFQ                         F1, Q, K, M                                                                     Q5 vs. Q1                                                                                                                                                                                                                          Age at cohort entry, history of diabetes mellitus, family history of pancreatic cancer, BMI, smoking status, pack-years of smoking, processed and red meat intake, and energy intake
  Bobe \[38\] 2008                Pancreas                                           Finland             16.1 (median)   306                        FFQ                         T, F1, F2, F4, Q, K, M, L, A, C, E   F1, F2, F4                                                                                                                                                                                                                                                                    Age at randomization, years of smoking, total number of cigarettes per day, self-reported history of diabetes mellitus, and energy-adjusted saturated fat intake
  Cutler \[39\] 2008              Lung                                               US                  \<18            849                        FFQ                         T, F1, F2, F3, F4, An, I             F1, F2, F3, F4, An, I, P                   T: 680.0 vs. 91.0, F1: 23.2 vs. 3.9, F2: 1.75 vs. 0.11, F3: 107.2 vs. 7.4, F4: 314.6 vs. 4.1, I: 1.83 vs. 0.07 (mean)                                                                                                              Age, energy, education level, race, BMI, multivitamin use, activity level, smoking history, and pack years
  Mursu \[40\] 2008               Lung                                               Finland             16.2 (mean)     62                         Food recording              T, F1, F2, F3, F4, An                F1, F2, F3, F4, An,                        T: 415.8 vs. 0.0 (energy adjusted mean)                                                                                                                                                                                            Age and examination years, BMI, smoking status, pack-years of smoking, physical activity, intakes of alcohol, total fat and saturated fat, and energy adjusted intake of fiber, vitamin C and E.
  Kurahashi \[41\] 2009           Liver                                              Japan               11.8 (mean)     m69/f32                    FFQ                         I (gen)                                                                         ≥20.0 vs. \<12.0 (m), ≥19.6 vs. \<12.2 (f)                                                                                                                                                                                         Age, area, HCV, HBsAg, smoking status, alcohol consumption, and intake of coffee and vegetables (+ menopausal status for women).
  Wang \[42\] 2009                Lung                                               US                  11.5 (mean)     241                        FFQ                         T, Q, K, M, L, A                     F1, F2,                                    T: 47.44 vs. 8.88, Q: 32.79 vs. 6.49, K: 13.06 vs. 0.86, M: 2.83 vs. 0.15, L: 0.20 vs. 0.01, A: 1.35 vs. 0.13 (median)                                                                                                             Age, race, total energy intake, randomized treatment assignment, smoking, alcohol use, physical activity, postmenopausal status, hormone replacement therapy use, multivitamin use, BMI, family history of colorectal cancer, ovary cancer, and breast cancer, and intake of fruit and vegetables, fiber, folate, and saturated fat.
  Bertoia \[43\] 2010             Renal                                              Finland             6.1 (median)    255                        FFQ                         T, Q, K, M, C, E                     F1, F4                                     T: 39.66 vs. 4.76, Q: 13.20 vs. 3.34, K: 4.26 vs. 0.13, M: 1.94 vs. 0.24, C: 7.37 vs. 0.18, E: 12.85 vs. 0.21 (mean)                                                                                                               Age, BMI, education level, measured systolic and diastolic blood pressure, self-reported history of hypertension, leisure-time physical activity, years of smoking, total number of cigarettes per day, trial intervention group, and alcohol consumption, total energy intake
  Shimazu \[44\] 2010             Lung                                               Japan               8 (median)      m481/f178                  FFQ                         I                                                                               Q4 vs. Q1                                                                                                                                                                                                                          Age, study area, smoking status, alcohol consumption, menopausal status in women, and total intake of vegetables, fruit, and fish.
  Hara \[45\] 2012                Stomach                                            Japan                               1249                       FFQ                         I (genistein)                                                                   Q4 vs. Q1, (median), 42.3 vs. 9.2 (m), 41.8 vs. 9.4 (f)                                                                                                                                                                            Age, public center area, BMI, smoking status, ethanol intake, family history of gastric cancer, vegetable, fruit, fish, salt, and total energy intake.
  Zamora-Ros \[46\] 2012          Stomach                                            10 Europe           11.0 (mean)     683                        FFQ, food records           T, F1, F2, F3, F4, An, I             F1, F2, F3, F4, An, I, P, Th               T: \>595.5 vs. \<200.4, F1: \>33.7 vs. \<15.0, F2: \>4.6 vs. \<1.2, F3: \>29.2 vs. \<6.1, F4: \>199.9 vs. \<26.1, An: \>32.8 vs. \<11.7, I: \>1.1 vs. \<0.3                                                                        Age, educational level, smoking status, physical activity, BMI, alcohol and energy intake, and daily consumption of fruit, vegetables, red and processed meat

a Lung and renal cell cancer were omitted in the analysis because updated articles were published using same cohort data.

T: total flavonoid intake, Q: quercetin, K: kaempferol, M: myricetin, L: luteolin, A: apigenin, H: hesperetin, N: naringenin, C: catechin, E: epicatechin, F1: flavonols, F2: flavones, F3: flavanones, F4: flavan-3-ols, An: anthocyanidins, I: isoflavones, P: proanthocyanidins, Th: theaflavins, Q4: highest quartile, Q5: highest quintile.

[Table 3](#pone-0075604-t003){ref-type="table"} shows the meta-analysis of the risk of smoking-related cancer in people with the highest intake of total dietary flavonoids compared with those with the lowest intake of total dietary flavonoids. Total dietary flavonoids were inversely associated with smoking-related cancer risk. However, in the subgroup analysis conducted by study design, this association was observed only in the case-control studies. Intake of total dietary flavonoids was inversely associated with smoking-related cancer risk among smokers, but the associations were not significant for the non-smokers. The summary estimate calculated for the association between total dietary flavonoids and aerodigestive tract cancer risk was significant (OR: 0.67, 95% CI: 0.54-0.83). The association with lung cancer risk was only marginally significant (OR: 0.84, 95% CI: 0.71-1.00).

10.1371/journal.pone.0075604.t003

###### Summary estimates for the effect of total dietary flavonoids on risk of smoking-related cancer ^[**a**](#ngtab3.1)^.

                             Summary    Heterogeneity          
  --------------------- ---- ---------- --------------- ------ -------
  All studies           15   **0.82**   **0.72-0.93**   52.9   0.008
  **Study design**                                             
  Case-control          10   **0.81**   **0.69-0.95**   43.8   0.067
  Cohort                5    0.82       0.65-1.04       53.5   0.072
  **Sex**                                                      
  Female                3    **0.66**   **0.49-0.88**   8.2    0.336
  Male                  3    0.96       0.77-1.18       0      0.820
  **Smoking status**                                           
  Smoker                7    **0.86**   **0.74-0.99**   45.7   0.087
  Non-smoker            7    1.01       0.88-1.15       37.0   0.146
  **Cancer site**                                              
  Aerodigestive tract   4    **0.67**   **0.54-0.83**   20.6   0.286
  Lung                  8    0.84       0.71-1.00       58.1   0.019
  Stomach               3    0.95       0.67-1.35       0      0.442
  Urinary organs        4    0.86       0.70-1.06       0      0.508

Random effects model was used if studies were heterogeneous (*p* \< 0.1).

Selected study numbers

*p* values for heterogeneity from Q-test

The summary estimates calculated for the association between the subclasses of dietary flavonoids and smoking-related cancer risk are presented in [Table 4](#pone-0075604-t004){ref-type="table"}. Dietary flavonols, flavones, flavanones, flavan-3-ols, and isoflavones significantly lowered the risk of smoking-related cancers, and the significant associations were maintained among the flavones, flavanones, and isoflavones in case-control studies. Flavonols were strongly associated with lower smoking-related cancer risk. The associations with flavonols were significant in only cohort studies, and all of the flavonol subgroups were significantly associated with smoking-related cancer risk if the fixed effects model was used. The subgroup analysis conducted by smoking status showed significantly different results. The dietary intake of flavonols, flavones, and flavanones was significantly associated with a lower risk of smoking-related cancer among smokers, but no association was observed among non-smokers, except for flavanones. Quercetin and kaempferol, the components of flavonols, showed significant associations, but flavonol myricetin showed no association. However, the associations with flavonol quercetin, kaempferol, and myricetin differed by smoking status. The components of flavones (luteolin and apigenin), flavanones (naringenin), and flavan-3-ols (catechin, epicatechin) were not significantly associated with smoking-related cancer risk, but hesperetin, a component of flavanones, was positively associated with smoking-related cancer risk.

10.1371/journal.pone.0075604.t004

###### Summary estimates for the effect of subclasses of dietary flavonoids on risk of smoking-related cancer^[**a**](#ngtab4.1)^.

                                Summary          Heterogeneity          Summary    Heterogeneity              Summary         Heterogeneity                                                  
  -------------- -------------- ---------------- --------------- ------ ---------- --------------- ---------- --------------- --------------- ------- ---- ---------- --------------- ------ -------
                 Flavonols      Flavones         Flavanones                                                                                                                                  
  All studies    15             **0.77**         **0.63-0.95**   70.3   \< 0.001   13              **0.77**   **0.69-0.85**   0               0.553   13   **0.77**   **0.64-0.92**   64.8   0.001
  Case-control   11             0.80             0.61-1.04       76.1   \< 0.001   10              **0.73**   **0.65-0.83**   0               0.735   11   **0.74**   **0.60-0.90**   67.6   0.001
  Cohort         4              **0.77**         **0.63-0.95**   39.2   0.176      3               0.86       0.70-1.06       34.6            0.217   2    0.97       0.75-1.24       0      0.650
  Female         5              **0.66**         **0.56-0.78**   17.0   0.306      3               **0.58**   **0.44-0.77**   0               0.667   4    **0.74**   **0.62-0.88**   32.8   0.215
  Male           5              **0.88**         **0.79-0.99**   0      0.621      3               **0.79**   **0.63-0.98**   0               0.628   4    **0.81**   **0.73-0.90**   0      0.637
  Smoker         8              **0.82**         **0.71-0.95**   51.4   0.044      5               **0.82**   **0.68-0.99**   67.8            0.014   7    **0.77**   **0.68-0.89**   61.5   0.016
  Non-smoker     8              0.84             0.69-1.03       62.4   0.009      5               0.99       0.89-1.11       1.9             0.396   7    **0.77**   **0.61-0.96**   74.4   0.001
                 Flavan-3-ols   Anthocyanidins   Isoflavones                                                                                                                                 
  All studies    15             **0.88**         **0.79-0.98**   16.2   0.264      12              0.89       0.79-1.01       0               0.649   11   **0.85**   **0.78-0.94**   30.7   0.146
  Case-control   11             0.90             0.80-1.01       0      0.483      10              0.90       0.79-1.03       0               0.476   7    **0.75**   **0.66-0.86**   0      0.560
  Cohort         4              0.71             0.45-1.12       54.0   0.089      2               0.86       0.66-1.13       0               0.847   4    0.96       0.84-1.09       0      0.424
  Female         3              **0.67**         **0.51-0.90**   0      0.439      3               0.78       0.57-1.08       0               0.406   6    0.91       0.67-1.22       59.6   0.030
  Male           3              1.03             0.83-1.28       0      0.551      3               0.97       0.76-1.23       0               0.996   6    0.84       0.69-1.03       51.5   0.067
  Smoker         6              0.94             0.79-1.12       56.4   0.043      5               0.92       0.86-1.00       4.7             0.380   5    0.86       0.72-1.04       55.5   0.061
  Non-smoker     6              0.99             0.91-1.07       15.4   0.315      5               1.33       0.95-1.88       61.3            0.035   5    0.78       0.59-1.02       55.5   0.062
                 Quercetin      Kaempferol       Myricetin                                                                                                                                   
  All studies    10             **0.80**         **0.67-0.96**   45.2   0.058      9               **0.85**   **0.74-0.97**   27.1            0.203   7    0.90       0.78-1.02       0      0.815
  Case-control   7              **0.75**         **0.59-0.97**   51.8   0.053      6               0.80       0.61-1.07       51.0            0.070   4    0.86       0.71-1.05       0      0.604
  Cohort         3              0.89             0.73-1.08       0      0.452      3               0.86       0.71-1.04       0               0.697   3    0.93       0.77-1.12       0      0.657
  Smoker         3              **0.60**         **0.46-0.80**   0      0.940      2               **0.50**   **0.34-0.72**   79.3            0.028   2    **0.64**   **0.45-0.89**   0      0.571
  Non-smoker     3              0.77             0.56-1.05       28.8   0.246      2               0.86       0.60-1.24       0               0.423   2    0.84       0.60-1.17       0      0.664
                 Luteolin       Apigenin         Hesperetin                                                                                                                                  
  All studies    3              0.99             0.76-1.29       0      0.450      1               \-         \-              \-              \-      2    **1.46**   **1.07-1.98**   0      0.390
                 Naringenin     Catechin         Epicatechin                                                                                                                                 
  All studies    2              0.96             0.52-1.76       85.6   0.008      3               0.74       0.53-1.03       60.0            0.082   3    0.82       0.66-1.01       4.1    0.352

Random effects model was used if studies were heterogeneous (*p* \< 0.1).

Selected study numbers

*p* values for heterogeneity from Q-test

[Table 5](#pone-0075604-t005){ref-type="table"} shows summary estimates for the effect of subclasses of dietary flavonoids on cancer risk by cancer site. In aerodigestive tract cancer including oral, larynx, pharynx, and esophageal cancer, most of flavonoids subclasses were significantly associated with reduced risk. In lung cancer, flavonol quercetin and kaempferol were inversely associated with cancer risk, but these associations were not observed in total flavonol intake and any other flavonoid subclasses**.**

10.1371/journal.pone.0075604.t005

###### Summary estimates for the effect of subclasses of dietary flavonoids on cancer risk by cancer site^[a](#ngtab5.1)^.

                               Summary    Heterogeneity          
  ------------------------ --- ---------- --------------- ------ -------
  Aerodigestive tract^d^                                         
  Flavonols                4   **0.61**   **0.38-0.99**   76.9   0.005
  Flavones                 4   **0.81**   **0.67-0.98**   0      0.826
  Flavanones               4   **0.57**   **0.43-0.76**   56.2   0.077
  Flavan-3ols              4   0.84       0.68-1.04       0      0.486
  Anthocyanidins           4   **0.77**   **0.62-0.97**   0      0.780
  Lung                                                           
  Flavonols                3   0.93       0.45-1.89       85.7   0.001
  Quercetin                5   **0.66**   **0.47-0.92**   49.6   0.094
  Kaempferol               5   **0.78**   **0.64-0.95**   0      0.871
  Myricetin                3   0.93       0.73-1.18       24.0   0.268
  Flavanones               3   0.93       0.62-1.41       70.3   0.034
  Flavan-3ols              5   0.91       0.69-1.19       52.0   0.080
  Urinary organs                                                 
  Quercetin                3   0.99       0.76-1.29       0      0.465
  Kaempferol               3   1.03       0.79-1.32       44.4   0.166
  Myricetin                3   1.13       0.75-1.71       0      0.935
  Flavan-3ols              3   0.83       0.64-1.06       0      0.460

Random effects model was used if studies were heterogeneous (*p* \< 0.1).

Selected study numbers

*p* values for heterogeneity from Q-test

oral, larynx, pharynx, and esophageal cancer

Subgroup analyses including less than 2 studies were omitted.

Discussion {#s4}
==========

Meta-analyses performed in this study including 19 case-controls (9,525 cases and 15,835 controls) and 15 cohort studies (988,082 subjects and 8,161 cases) showed various results according to flavonoid type, smoking status, and cancer site. However, overall results revealed that dietary flavonoids were inversely associated with the risk of smoking-related cancers, and the associations were more prominent among smokers.

The summary estimates suggested that total dietary flavonoids and several flavonoid subclasses were associated with reduced risks of smoking-related cancers. Total dietary flavonoids were inversely associated with smoking-related cancer risk in both the case-control and cohort studies, although a non-significant association was observed in the cohort studies. Flavones, flavanones, isoflavones, and flavonol quercetin were inversely associated with the risk of smoking-related cancers in only the case-control studies. Similar results were shown in our previous meta-analysis of colorectal and stomach cancers \[[@B9]\]. Significant associations were observed in the summary estimates of only the case-control studies, which are subject to more recall bias than cohort studies. However, the non-significant results might be caused by low statistical power due to the small numbers of cohort studies in the present study. In the summary estimates of cohort studies, dietary flavonols were significantly associated with a reduced risk of smoking-related cancer, and total flavonoids were also significantly associated with the reduced risk when the fixed effects model was applied. Thus, in contrast to previous study of colorectal and stomach cancers \[[@B9]\], dietary flavonoids may play a role in reducing smoking-related cancer risk. The preventative effects of dietary flavonoids may differ by cancer site among the smoking-related cancers. Lung cancer, which is mostly caused by tobacco smoke, was the most commonly studied cancer site, but total dietary flavonoids was only marginally associated with lung cancer in the present study. Significant association between flavonoids and lung cancer risk was observed in the previous meta-analysis \[[@B47]\]. In their study, summary estimate of flavonoids were combined all studies reported total flavonoid intake and their subclasses altogether. However, the results of each flavonoid subclasses were similar. Kaempferol alone showed significant association with reduced lung cancer risk in the previous meta-analysis, and quercetin, although it is not statistically significant, showed most reduced risk of lung cancer. In our study, quercetin and kaempferol were significantly associated with reduced risk of lung cancer. Intake of total dietary flavonoids and most of their subclasses was significantly associated with aerodigestive tract cancer risk. Dietary flavonoids were not significantly associated with risk of cancer at any other site. The limited number of studies that were eligible for the subgroup analyses conducted by cancer site rendered the results inconclusive. However, the lower risk of cancers of the aerodigestive tract may be closely related to the protective effects of dietary flavonoids.

The protective effects of flavonoids on cancer risk have been explained by several mechanisms. Flavonoids are polyphenolic compounds that are known to have antioxidant properties, so the free radical scavenging properties of flavonoids are closely related to the beneficial effects on cancer risk. The strong antioxidant properties of flavonoids effectively reduced various types of oxidants \[[@B48],[@B49]\]. However, direct antioxidant activities of dietary flavonoids may not be the only explanation of the protective effects on cancer risk \[[@B50],[@B51]\]. Dietary flavonoids are found at very low concentrations in human plasma due to their low bioavailability. The bioavailability of dietary flavonoids can vary according to their chemical structure and food sources. The bioavailability of isoflavones and quercetin was relatively high, whereas that of tea catechins and anthocyanins is very low \[[@B50],[@B52]\]. The other explanation for the beneficial effects of flavonoids on cancer is that flavonoids play a role in regulating enzymatic pathways. Carcinogens that enter the body are first metabolized to more active forms by phase I enzymes such as cytochrome P450 (CYP), and the active forms can be detoxified by phase II enzymes such as UDP-glucuronyl transferase, glutathione S-transferase, and quinone reductase. Flavonoids are responsible for the inactivation of phase I enzymes as well as the activation of phase II enzymes \[[@B53]\].

Several studies examined for this meta-analysis performed a subgroup analysis by smoking status. Total flavonoid intake was associated with a reduced cancer risk among smokers but not among non-smokers. These different associations were observed for dietary flavonols, flavones, flavanones, and the flavonol components quercetin, kaempferol, and myricetin. Because smoking can increase oxidative stress, dietary flavonoids may function as antioxidants; therefore, the more prominent effects of flavonoids on the reduced cancer risk may be more likely to be observed among smokers. Smokers have lower levels of some antioxidants in their plasma than non-smokers, suggesting the larger involvement of these antioxidants in smokers \[[@B54]\]. Similar results were observed in a previous meta-analysis of dietary flavonoids and the risk of lung cancer, and the results suggested that flavonoids function as antioxidants to reduce the lung cancer risk in smokers \[[@B47]\]. However, the antioxidant activities of dietary flavonoids might be limited due to their low bioavailability, as discussed earlier. Tobacco has many types of carcinogens including PAH, benzo\[a\]pyrene (BaP), N-nitroso compound, and 4-aminobiphenyl, and these carcinogens and their metabolites can cause gene mutations such as p53 mutations and the formation of DNA or protein adducts \[[@B8]\]. Dietary flavonoids protect human hepatoma cells from N-nitrosodimethylamine-, N-nitrosopyrrolidine- and BaP-induced DNA damage \[[@B55]\]. Associations between CYP1A1 and lung squamous cell carcinoma (SCC) and associations between CYP2E1 and lung adenocarcinoma (AC) were observed, suggesting a specificity of tobacco smoke PAHs for lung SCC and tobacco-specific nitrosamines for lung AC \[[@B56]\]. Quercetin inhibited the CYP450 enzymes that were activated by BaP \[[@B57]\], and the relationship between the consumption of onions rich in flavonoids and lung cancer risk was modified by CYP1A1 \[[@B17]\]. Dietary flavonoids may protect against carcinogenesis by modulating enzymatic pathways, suggesting that dietary flavonoids can function as anti-tumor agents among smokers.

Flavonoids may be associated with early carcinogenesis \[[@B58]\], suggesting that the cohort design is more suitable for association studies, but only a limited number of cohort studies have been published. Definition of high vs. low intake of flavonoids was slightly different across studies, which may result in high heterogeneity in the meta-analysis. Bioactive food components are highly correlated, and the bioavailability of dietary flavonoids differ considerably by food source, even among the same flavonoid types. Previous work has suggested that flavonoid food sources rather than specific flavonoids should be analyzed for associations with disease risk \[[@B59]\]. However, consistent associations between dietary flavonoids and their subclasses and smoking-related cancer risk were observed in the studies reviewed here. Furthermore, the subgroup analysis conducted by smoking status showed a consistently inverse association between dietary flavonoids and smoking-related cancer risk. Thus, despite these limitations, the present meta-analysis showed that dietary flavonoids are inversely associated with smoking-related cancer risk.

Although the protective effects of flavonoids varied according to cancer site and flavonoid type, the overall results indicated that dietary flavonoids might have preventative effects against smoking-related cancers. The beneficial effects of flavonoids on cancer risk were more prominent among smokers than non-smokers. Total flavonols and flavonol quercetin may be the most powerful agents for smoking-induced carcinogenesis. Thus, we suggest that smokers might benefit from a flavonoid-rich diet.
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